Modulation of SF3B1 in the pre-mRNA spliceosome induces a RIG-I-dependent type I IFN response
Open Access
- 5 October 2021
- journal article
- research article
- Published by Elsevier in Journal of Biological Chemistry
- Vol. 297 (5) , 101277
Abstract
No abstract availableKeywords
Funding Information
- Pfizer
This publication has 55 references indexed in Scilit:
- Coherence between Cellular Responses and in Vitro Splicing Inhibition for the Anti-tumor Drug Pladienolide B and Its AnalogsJournal of Biological Chemistry, 2014
- The spliceosome as a target of novel antitumour drugsNature Reviews Drug Discovery, 2012
- STING Mediates Neuronal Innate Immune Response Following Japanese Encephalitis Virus InfectionScientific Reports, 2012
- Biological validation that SF3b is a target of the antitumor macrolide pladienolideThe FEBS Journal, 2011
- Frequent pathway mutations of splicing machinery in myelodysplasiaNature, 2011
- Immune Signaling by RIG-I-like ReceptorsImmunity, 2011
- Reduced fidelity of branch point recognition and alternative splicing induced by the anti-tumor drug spliceostatin AGenes & Development, 2011
- Recognition of RNA virus by RIG-I results in activation of CARD9 and inflammasome signaling for interleukin 1β productionNature Immunology, 2009
- The Adaptor Protein MITA Links Virus-Sensing Receptors to IRF3 Transcription Factor ActivationImmunity, 2008
- Function of RIG-I-like Receptors in Antiviral Innate ImmunityJournal of Biological Chemistry, 2007